跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 151,236 条关于
“Low-grade serous ovarian cancer”
全部
151,236
临床试验
127,415
药物
3,010
机构
1,232
资讯
19,579
3年前
Avutometinib-Defactinib Combination Shows 45% Response Rate in Low-Grade Serous Ovarian Cancer
3年前
Avutometinib Plus Defactinib Shows Promise in Recurrent Low-Grade Serous Ovarian Cancer
去年
Avutometinib Plus Defactinib NDA Filed for KRAS-Mutant Low-Grade Serous Ovarian Cancer
去年
Verastem Oncology Completes FDA Submission for Avutometinib Plus Defactinib in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
去年
Verastem Oncology Completes FDA Submission for Avutometinib and Defactinib in Recurrent KRAS-Mutant Low-Grade Serous Ovarian Cancer
去年
Ribociclib-Letrozole Combo Shows Promising 24% Response Rate in Low-Grade Serous Ovarian Cancer Trial
去年
Avutometinib and Defactinib Rolling NDA Completed for KRAS-Mutated Low-Grade Serous Ovarian Cancer
去年
Avutometinib and Defactinib Show Promise in Recurrent Low-Grade Serous Ovarian Cancer
去年
Verastem's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
去年
Molecular Testing Advances Personalized Treatment Strategies in Ovarian Cancer
第 1 页，共 1958 页
上一页
下一页
